Dosimetric Comparison of 3D Conformal Conventional Radiotherapy versus Intensity-Modulated Radiation Therapy both in Conventional and High Dose Radiation for Prostate Carcinoma
<span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">Background: Radiotherapy plays an important role in the management of prostate cancer. There are ongoing efforts...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Kasr Al-Ainy Center of Clinical Oncology and Nuclear Medicine
2016-06-01
|
| Series: | Research in Oncology |
| Subjects: | |
| Online Access: | https://resoncol.journals.ekb.eg/article_588_7981efaeefbb1133810f20f24c578fff.pdf |
| Summary: | <span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">Background: Radiotherapy plays an important role in the management of prostate cancer. There are ongoing efforts to deliver the optimum radiation dose to the prostate while minimizing it to at risk pelvic structures.</span></span>
<span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">Aim: T<span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">o compare the dose coverage of planning target volume (PTV) and organs-at-risk (OAR) between intensity-modulated radiation therapy (IMRT) and conventional three dimensiona</span></span><span style="font-family: Tahoma,Tahoma; font-size: small;"><span style="font-family: Tahoma,Tahoma; font-size: small;">l </span></span><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">conformal radiotherapy (3D-CRT) for the same plan of prostate cancer patients in both conventional dose and high dose. </span></span></span></span></span></span>
<span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">Methods: <span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">Plans of 15 prostate cancer patients with low- or intermediate risk, treated by 3D-CRT, were compared with IMRT to the same dose and to a higher dose. We used XIO- treatment planning system for 3D-CRT and Monaco treatment planning system for IMRT. </span></span></span></span></span></span></span></span>
<span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">Results: <span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">Mean and minimum dose to PTV were equal, but the mean maximum dose was significantly higher </span></span><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">in IMRT (72Gy) than 3D-CRT. Doses to critical organs in IMRT plans were lower than 3D-CRT, even in the increased dose of 80Gy. </span></span></span></span></span></span></span></span></span></span>
<span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">Conclusion: <span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">IMRT is recommended as the standard of care in treatment of prostate carcinoma. Applying escalated dose is recommended. </span></span></span></span></span></span></span></span></span></span></span></span> |
|---|---|
| ISSN: | 2357-0687 2357-0695 |